'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

Canaccord lowered the firm’s price target on Cybin (CYBN) to $86 from $96 and keeps a Buy rating on the shares. The firm said they ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

The Philomath City Council continued its review of psilocybin regulation options during its regular monthly meeting Tuesday and approved two draft ordinances.

( MENAFN - GlobeNewsWire - Nasdaq) LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based ...

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulationSingle-Ascending Dosing (SAD) study to evaluate safety and ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...